Modernatx, Inc.

Vanderbilt University

Giuseppe Ciaramella

Eric Yi-Chun Huang

Tal Zaks

Shinu John

Kapil Bahl

Sayda Mahgoub Elbashir

Kerry Benenato

Stephen G Hoge

Sunny Himansu

Axel Bouchon

Andrew J Bett

Lan Zhang

Kambiz Mousavi

Amy Espeseth

Dai Wang

Christine Shaw

Pedro Cejas

Vladimir Presnyak

Ellalahewage Sathyajith Kumarasinghe

James E Crowe, Jr

Kerim Babaoglu

Danilo R Casimiro

David C Nickle

Tai Zaks

Jessica Anne Flynn

Nicholas Valiante

Eric Yi-Chen Huang

The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The vaccine can be formulated in a lipid nanoparticle.

RSV RNA vaccines

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to mRNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Betacoronavirus mRNA vaccines

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Influenza vaccine

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

Betacorona virus mRNA vaccines

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Betacoronavirus MRNA vaccines

The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Nucleic acid vaccines

Betacoronavirus RNA vaccines

The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.

Concatemeric peptide epitope RNAs

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having a open reading reading frame encoding at least varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

Varicella zoster virus (VZV) vaccine

Combination HMPV/RSV RNA vaccines

This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.

Polynucleotides encoding anti-chikungunya virus antibodies

Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Herpes simplex virus vaccine

Growing community of inventors

Sudbury, MA, United States of America

Giuseppe Ciaramella